ReviewArtificial organs2023
Bioethical implications of organ-on-a-chip on modernizing drug development.
Review in Artificial organs, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 18 citations in OpenAlex.
- Emerging organoids and organoids-on-chip platforms for translational development of antibody‒drug conjugates and next-generation bioconjugates.Acta pharmaceutica Sinica. B · 2026Review
- Ethical Challenges and Governance Strategies for Microphysiological Systems Technology.Biology · 2026Review
- Microengineered bone models: advances and applications of bone-on-a-chip technology.Journal of biological engineering · 2026Review
- Recapitulating lung cancer metastasisOncology reports · 2026Review
- Ethical review key considerations for organoid applications in biomedical research-a systematic review.Frontiers in cell and developmental biology · 2026Review
- Application and prospects of organoid-on-a-chip in research on the intestinal mucosal barrier.Burns & trauma · 2026Review
- The ethical aspects of human organ-on-chip models: A mapping review.Stem cell reports · 2025Review
- Progress in monitoring molecular, cellular and metabolic dynamics using mass spectrometry imaging.Bioanalysis · 2025Review
- Brain organoids-on-chip for neural diseases modeling: History, challenges and trends.Journal of pharmaceutical analysis · 2025Review
- Cancer-on-a-chip for precision cancer medicine.Lab on a chip · 2025Review
- Patient-derived esophageal adenocarcinoma organ chip: a physiologically relevant platform for functional precision oncology.Journal of translational medicine · 2025Article
- Cyber-physical security of biochips: A perspective.Biomicrofluidics · 2025Article
- Strategies for promoting neurovascularization in bone regeneration.Military Medical Research · 2025Review
- Recent Progress in PDMS-Based Microfluidics Toward Integrated Organ-on-a-Chip Biosensors and Personalized Medicine.Biosensors · 2025Review
- Neuroinflammation-on-a-chip for multiple sclerosis research: a narrative review.Annals of medicine and surgery (2012) · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
Organ-on-chips are three-dimensional microdevices that emulate the structure, functionality, and behavior of specific tissues or organs using human cells. Combining organoids with microfabricated fluidic channels and microelectronics, these systems offer a promising platform for studying disease mechanisms, drug responses, and tissue performance. By replicating the in vivo microenvironment, these devices can recreate complex cell interactions in controlled conditions and facilitate research in various fields, including drug toxicity and efficacy studies, biochemical analysis, and disease pathogenesis. Integrating human induced pluripotent stem cells further enhances their applicability, thereby enabling patient-specific disease modeling for precision medicine. Although challenges like economy-of-scale, multichip integration, and regulatory compliance exist, advances in this modular technology show promise for lowering drug development costs, improving reproducibility, and reducing the reliance on animal testing. The ethical landscape surrounding organ-on-chip usage presents both benefits and concerns. While these chips offer an alternative to animal testing and potential cost savings, they raise ethical considerations related to community engagement, informed consent, and the need for standardized guidelines. Ensuring public acceptance and involvement in decision-making is vital to address misinformation and mistrust. Furthermore, personalized medicine models using patient-derived cells demand careful consideration of potential ethical dilemmas, such as modeling physiological functions of fetuses or brains and determining the extent of protection for these models. To achieve the full potential of organ-on-a-chip models, collaboration between scientists, ethicists, and regulators is essential to fulfil the promise of transforming drug development, advancing personalized medicine, and contributing to a more ethical and efficient biomedical research landscape.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.